Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients

T. Tarr, G. Lakos, H. Bhattoa, Y. Shoenfeld, G. Szegedi, E. Kiss

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The objective of this study was to characterize risk factors for thrombotic events in lupus patients. A total of 272 lupus patients were followed up for five years during which the presence of aPL antibodies [anticardiolipin (aCL), anti-beta2-glycoprotein I (aβ2GPI) and lupus anticoagulant (LAC)] were determined, and all thrombotic incidents and antithrombotic therapy-related data were collected. At baseline, three groups were constituted, an aPL- group with 107 aPL negative patients, an aPL+ group with 81 aPL positive patients without clinical thrombosis and a secondary antiphospholipid syndrome (APS) group with 84 aPL+ patients who met the Sapporo criteria. LAC was more common in the APS than the aPL+ group (32.1% versus 9.9%, P <0.001). The prevalence of clinical thrombotic events was significantly higher when all three types of aPL were present compared to only aCL positive cases. During follow up, aPL appeared in 7.5% of the aPL- group, and 2.8% of this group had thrombotic complications. In the aPL+ group, thrombotic events reoccurred in 1.9% of those receiving antithrombotic prophylaxis and 6.9% of those without primary prophylaxis. Despite anticoagulant therapy, thrombotic events reoccurred in 8.3% of the APS group. These findings indicate that LAC, constant and cumulative presence of aPL and previous thrombosis are positive predictors for the development of thrombotic complication in lupus patients.

Original languageEnglish
Pages (from-to)39-45
Number of pages7
JournalLupus
Volume16
Issue number1
DOIs
Publication statusPublished - 2007

Fingerprint

Antiphospholipid Antibodies
Lupus Coagulation Inhibitor
Antiphospholipid Syndrome
Thrombosis
beta 2-Glycoprotein I
Anticardiolipin Antibodies
Anticoagulants
Anti-Idiotypic Antibodies
Therapeutics

Keywords

  • Antiphospholipid antibodies
  • Antiphospholipid syndrome
  • Primary prophylaxis
  • SLE
  • Thrombosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. / Tarr, T.; Lakos, G.; Bhattoa, H.; Shoenfeld, Y.; Szegedi, G.; Kiss, E.

In: Lupus, Vol. 16, No. 1, 2007, p. 39-45.

Research output: Contribution to journalArticle

@article{1ab3b4c71a71488ca4a16c67ad97d26e,
title = "Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients",
abstract = "The objective of this study was to characterize risk factors for thrombotic events in lupus patients. A total of 272 lupus patients were followed up for five years during which the presence of aPL antibodies [anticardiolipin (aCL), anti-beta2-glycoprotein I (aβ2GPI) and lupus anticoagulant (LAC)] were determined, and all thrombotic incidents and antithrombotic therapy-related data were collected. At baseline, three groups were constituted, an aPL- group with 107 aPL negative patients, an aPL+ group with 81 aPL positive patients without clinical thrombosis and a secondary antiphospholipid syndrome (APS) group with 84 aPL+ patients who met the Sapporo criteria. LAC was more common in the APS than the aPL+ group (32.1{\%} versus 9.9{\%}, P <0.001). The prevalence of clinical thrombotic events was significantly higher when all three types of aPL were present compared to only aCL positive cases. During follow up, aPL appeared in 7.5{\%} of the aPL- group, and 2.8{\%} of this group had thrombotic complications. In the aPL+ group, thrombotic events reoccurred in 1.9{\%} of those receiving antithrombotic prophylaxis and 6.9{\%} of those without primary prophylaxis. Despite anticoagulant therapy, thrombotic events reoccurred in 8.3{\%} of the APS group. These findings indicate that LAC, constant and cumulative presence of aPL and previous thrombosis are positive predictors for the development of thrombotic complication in lupus patients.",
keywords = "Antiphospholipid antibodies, Antiphospholipid syndrome, Primary prophylaxis, SLE, Thrombosis",
author = "T. Tarr and G. Lakos and H. Bhattoa and Y. Shoenfeld and G. Szegedi and E. Kiss",
year = "2007",
doi = "10.1177/0961203306074767",
language = "English",
volume = "16",
pages = "39--45",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients

AU - Tarr, T.

AU - Lakos, G.

AU - Bhattoa, H.

AU - Shoenfeld, Y.

AU - Szegedi, G.

AU - Kiss, E.

PY - 2007

Y1 - 2007

N2 - The objective of this study was to characterize risk factors for thrombotic events in lupus patients. A total of 272 lupus patients were followed up for five years during which the presence of aPL antibodies [anticardiolipin (aCL), anti-beta2-glycoprotein I (aβ2GPI) and lupus anticoagulant (LAC)] were determined, and all thrombotic incidents and antithrombotic therapy-related data were collected. At baseline, three groups were constituted, an aPL- group with 107 aPL negative patients, an aPL+ group with 81 aPL positive patients without clinical thrombosis and a secondary antiphospholipid syndrome (APS) group with 84 aPL+ patients who met the Sapporo criteria. LAC was more common in the APS than the aPL+ group (32.1% versus 9.9%, P <0.001). The prevalence of clinical thrombotic events was significantly higher when all three types of aPL were present compared to only aCL positive cases. During follow up, aPL appeared in 7.5% of the aPL- group, and 2.8% of this group had thrombotic complications. In the aPL+ group, thrombotic events reoccurred in 1.9% of those receiving antithrombotic prophylaxis and 6.9% of those without primary prophylaxis. Despite anticoagulant therapy, thrombotic events reoccurred in 8.3% of the APS group. These findings indicate that LAC, constant and cumulative presence of aPL and previous thrombosis are positive predictors for the development of thrombotic complication in lupus patients.

AB - The objective of this study was to characterize risk factors for thrombotic events in lupus patients. A total of 272 lupus patients were followed up for five years during which the presence of aPL antibodies [anticardiolipin (aCL), anti-beta2-glycoprotein I (aβ2GPI) and lupus anticoagulant (LAC)] were determined, and all thrombotic incidents and antithrombotic therapy-related data were collected. At baseline, three groups were constituted, an aPL- group with 107 aPL negative patients, an aPL+ group with 81 aPL positive patients without clinical thrombosis and a secondary antiphospholipid syndrome (APS) group with 84 aPL+ patients who met the Sapporo criteria. LAC was more common in the APS than the aPL+ group (32.1% versus 9.9%, P <0.001). The prevalence of clinical thrombotic events was significantly higher when all three types of aPL were present compared to only aCL positive cases. During follow up, aPL appeared in 7.5% of the aPL- group, and 2.8% of this group had thrombotic complications. In the aPL+ group, thrombotic events reoccurred in 1.9% of those receiving antithrombotic prophylaxis and 6.9% of those without primary prophylaxis. Despite anticoagulant therapy, thrombotic events reoccurred in 8.3% of the APS group. These findings indicate that LAC, constant and cumulative presence of aPL and previous thrombosis are positive predictors for the development of thrombotic complication in lupus patients.

KW - Antiphospholipid antibodies

KW - Antiphospholipid syndrome

KW - Primary prophylaxis

KW - SLE

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=33846616931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846616931&partnerID=8YFLogxK

U2 - 10.1177/0961203306074767

DO - 10.1177/0961203306074767

M3 - Article

VL - 16

SP - 39

EP - 45

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 1

ER -